



Issued: 16 June 2025, Philadelphia, PA

GSK announces the Linked by Lupus: Optimal Care Initiative to help support individuals with lupus in the US

- Grant funding will be provided to support national, state, and local non-profit organizations and community-based groups focused on lupus
 - New resources and tools will support implementation of community-led programs designed to improve earlier diagnosis, enhance awareness of and access to evidence-based treatment, and/or advance communication between patients and providers
 - Deadline for proposals is September 1, 2025
-

GSK plc (LSE/NYSE: GSK) today announced the launch of the Linked by Lupus: Optimal Care Initiative to help support individuals impacted with lupus, particularly systemic lupus erythematosus (SLE) and lupus nephritis (LN).

“Too many people living with lupus face delays in diagnosis and disconnects in care,” said Court Horncastle, Senior Vice President at GSK. “With this initiative, we’re proud to support the organizations working within local communities to improve diagnosis, access to optimal care, and connection for those impacted by lupus.”

GSK is seeking proposals for community-driven initiatives aimed at improving earlier diagnosis and recognition of lupus signs and symptoms; enhancing awareness of and access to evidence-based treatment options; and/or advancing communication between patients and providers regarding lupus.

GSK is committing up to \$1 million USD in grant funding to support national, state, and local non-profit organizations and community-based groups focused on lupus. This program is in addition to existing funding opportunities GSK provides to support the critical work of partner organizations within the lupus ecosystem. GSK recognizes the pivotal leadership demonstrated by these types of groups and the need to sustain their important work as patient advocates.

Eligible organizations should respond to the Call for Grant Applications (CGA) with programming that aligns with the Linked by Lupus: Optimal Care Initiative mission to support people impacted by lupus and help create a sustainable lupus community that fosters a sense of belonging, shared understanding, and mutual support among patients and care partners in the US. Grant proposals are due by September 1, 2025 and will be reviewed and approved according to set principles and criteria. To receive the principles and criteria, please email juliet.x.freudman@gsk.com.

Press release

For media and investors only



The grant application process is now open on gskfunding.com. When submitting your request, please use the following format in your project title: **Linked by Lupus: [insert your grant title]**.

GSK will coordinate regular convenings with external stakeholders and harness existing forums to share best practices in addressing health inequities in lupus, empowering public health organizations and communities with actionable models to help bring successful efforts to scale.

More information is available at www.GSKgrants.com.

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.

GSK inquiries

Media:

Kathleen Quinn	+1 202 603 5003	(Washington DC)
Lyndsay Meyer	+1 202 302 4595	(Washington DC)

Investor Relations:

Jeff McLaughlin	+1 215 751 7002	(Philadelphia)
Frannie DeFranco	+1 215 751 3126	(Philadelphia)

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2024, and GSK's Q1 Results for 2025.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street
London
WC1A 1DG